D Sommariva
Overview
Explore the profile of D Sommariva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branchi A, Fiorenza A, Torri A, Muzio F, Berra C, Colombo E, et al.
Nutr Metab Cardiovasc Dis
. 2002 Jul;
12(1):24-8.
PMID: 12125226
Background And Aim: It has been reported that atorvastatin increases high-density lipoprotein cholesterol (HDL-C) more in patients with low than in those with high baseline HDL-C levels. This may have...
2.
Branchi A, Fiorenza A, Torri A, Muzio F, Berra C, Colombo E, et al.
Clin Ther
. 2001 Jul;
23(6):851-7.
PMID: 11440285
Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20-80 mg/d). Data on the effects...
3.
Fiorenza A, Branchi A, Sommariva D
Int J Clin Lab Res
. 2001 Feb;
30(3):141-5.
PMID: 11196072
The association of cancer with low serum total cholesterol is well established. Less clear is the relationship of cancer with the cholesterol distribution among the different lipoprotein classes. Conflicting results...
4.
Branchi A, Fiorenza A, Rovellini A, Torri A, Muzio F, Macor S, et al.
Eur J Clin Pharmacol
. 1999 Sep;
55(7):499-502.
PMID: 10501818
Objectives: The main effect of statins is the decrease of serum level of low-density lipoprotein (LDL) cholesterol, due to the inhibition of intracellular cholesterol biosynthesis which brings about an upregulation...
5.
Branchi A, Rovellini A, Torri A, Sommariva D
Diabetes Care
. 1998 Sep;
21(9):1397-402.
PMID: 9727883
Objective: To evaluate the accuracy of LDL cholesterol calculated with Friedewald's equation in the assessment of cardiovascular risk in NIDDM patients. Research Design And Methods: The calculation of LDL cholesterol...
6.
Branchi A, Rovellini A, Tomella C, Sciariada L, Torri A, Molgora M, et al.
Eur J Clin Nutr
. 1997 Jun;
51(6):362-5.
PMID: 9192192
Objective: To investigate the relationship between alcohol intake and serum level of high-density lipoprotein (HDL) subfractions defined on the basis of their apolipoprotein A-I and A-II content (LpA-I and LpA-I:...
7.
Branchi A, Rovellini A, Fiorenza A, Maraffi F, Gandini R, Sommariva D
Int J Clin Pharmacol Ther
. 1996 Sep;
34(9):384-9.
PMID: 8880287
The main effect of simvastatin is the decrease of serum cholesterol due to the reduction of LDL. A decrease of serum triglycerides and an increase of HDL-C are commonly observed...
8.
Fiorenza A, Branchi A, Cardena A, Molgora M, Rovellini A, Sommariva D
Int J Clin Lab Res
. 1996 Jan;
26(1):37-42.
PMID: 8739854
Epidemiological surveys indicate an inverse relationship between cancer occurrence and serum cholesterol. Low serum cholesterol might be either a risk factor for cancer or the effect of factors associated with...
9.
Branchi A, Rovellini A, Fiorenza A, Sommariva D
Int J Clin Pharmacol Ther
. 1995 Jun;
33(6):345-50.
PMID: 7582386
Lp(a) level is relatively stable in each individual and is mainly under genetic control. Attempts made to lower Lp(a) with pharmacological means gave conflicting results. In order to further evaluate...
10.
Branchi A, Rovellini A, Sommariva D
Int J Clin Pharmacol Res
. 1995 Jan;
15(4):153-8.
PMID: 8871265
On the basis of apoprotein composition, high-density lipoprotein (HDL) particles may be subdivided into two main subpopulations defined by the presence in the lipoprotein molecule of apo A-I (Lp A-I)...